MedWatch·Industry news·Business & finance·6d agoDemant on track for best quarter since the turn of the millenniumDemant's record-breaking quarter signals strong market demand for the Oticon Zeal platform, which may influence product availability, competitive pricing, and the broader hearing aid market landscape.
MedWatch·Financial report·Business & finance·9d agoMorgan Stanley upgrades Demant and Sonova on positive market prospectsA Morgan Stanley upgrade signals that institutional investors expect a hearing aid market recovery, which could translate into increased R&D spending and product innovation from two of the industry's largest manufacturers.＋Save
MedWatch·Industry news·Hearing aids·2w agoDemant product stands out in new market analysisStrong investor-driven preference data for the Oticon Zeal signals meaningful competitive pressure in the premium hearing aid segment that clinic owners and dispensers should monitor when making stocking decisions.＋Save
MedWatch·Financial report·Business & finance·3w agoAnalysts see prospects for upward revision at Demant after strong 2026 startA broadly improving hearing aid market signals potentially greater investment in R&D, product innovation, and access initiatives that could shape the audiology landscape over the coming years.＋Save
MedWatch·Industry news·Hearing aids·3w agoDemant reaps rewards of a popular relaunch among US veteransSecuring a VA supply contract is a significant commercial milestone that shifts market share within the largest single hearing aid dispensing channel in the US.＋Save
Audiology Worldnews·Industry news·Business & finance·5w agoDemant completes divestment of Oticon MedicalDemant's complete exit from implantable hearing solutions reshapes the competitive landscape for bone-anchored and cochlear implant markets, potentially affecting clinician supplier choices and long-term product continuity.＋Save
MedWatch·Industry news·Regulatory & legal·5w agoDemant CEO warns about new EU AI regulationsEU AI regulation could slow the development pipeline and market availability of AI-powered hearing devices, with downstream effects on the full audiology supply chain.＋Save
Hearing Tracker·Industry news·Business & finance·6w agoDemant Names Bassel Rifai President of Hearing AidsLeadership transitions at top-five hearing aid manufacturers can influence product strategy, partnership priorities, and market direction for the broader audiology field.＋Save
MedWatch·Financial report·Business & finance·8w agoDanske Bank sees promising outlook for Demant after strong Q1Investor confidence in Demant signals continued R&D and commercial momentum for Oticon products, which may shape future device availability and competition in the hearing aid market.＋Save
MedWatch·Financial report·Business & finance·8w agoDemant delivers strong start to the year on relaunch momentumDemant's relaunch-driven momentum suggests the company is prioritizing portfolio refresh over entirely new platforms, which may affect the pace of clinically meaningful innovation in the near term.＋Save
MedWatch·Industry news·Business & finance·8w agoJyske Bank: Demant’s strong start points to high-end resultsPositive analyst coverage can reflect and reinforce investor confidence in Demant's portfolio strategy, indirectly signaling stability for the audiologists and dispensers who rely on their products.＋Save
MedWatch·Industry news·Business & finance·8w agoDemant CEO teases new launches: "Our platform is very strong"Anticipated Demant product launches could shift competitive dynamics in the premium hearing aid segment and affect dispensing choices for clinicians.＋Save
MedWatch·Financial report·Business & finance·8w agoDemant maintains guidance, sees lower-end outcome as "less likely"Demant's confidence in its growth trajectory signals continued investment capacity in hearing technology R&D and market expansion.＋Save
Hearing Tracker·Financial report·Business & finance·8w agoDemant Reports 6% Organic Growth in Q1 2026, Driven by Strong Oticon Zeal LaunchDemant's growth driven by the Oticon Zeal launch signals continued market momentum in premium hearing aids, which may influence product availability, pricing competition, and clinic purchasing decisions.＋Save
MedWatch·Financial report·Business & finance·8w agoDanske Bank sees potential focus on Demant’s miniature product launch and GN’s sale to Amplifon in interim reportA potential GN–Amplifon deal and Demant's product pipeline are market-shaping events that could alter competitive dynamics, pricing, and product availability across audiology clinics globally.＋Save
MedWatch·Industry news·Hearing aids·8w agoDemant launches Oticon Zeal through retail channels in the USInclusion of a new hearing aid in the VA contract significantly expands its reach to one of the largest publicly funded hearing healthcare populations in the US.＋Save
Hearing Tracker·Financial report·Business & finance·4mo agoDemant Reports 2025 Revenue Growth but Lower Profits, Forcing Cost Cutting ProgramCost-cutting at a major hearing aid manufacturer could eventually affect product development timelines, workforce, and supply partnerships across the audiology industry.＋Save
Hearing Tracker·Industry news·Business & finance·6mo agoDemant Sells EPOS to ACCO Brands to Focus Fully on Hearing HealthcareDemant's divestiture of a non-core audio brand signals a sharpened industry focus on hearing healthcare, which could accelerate product investment and affect competitive dynamics for clinics that carry Demant-affiliated brands.＋Save
